tiprankstipranks
Fate Therapeutics (FATE)
NASDAQ:FATE
US Market

Fate Therapeutics (FATE) Ownership - Who Owns Fate Therapeutics?

Compare
1,169 Followers

Fate Therapeutics (FATE) Ownership Overview

18.11%15.88%39.29%10.34%16.39%
18.11% Insiders
39.29% Other Institutional Investors
10.34% ETFs
16.39% Public Companies and
Individual Investors
The ownership structure of Fate Therapeutics (FATE) stock is a mix of institutional, retail, and individual investors. Approximately 65.51% of the company’s stock is owned by Institutional Investors, 18.11% is owned by Insiders, and 16.39% is owned by Public Companies and Individual Investors.
The ownership structure of Fate Therapeutics (FATE) stock is a mix of institutional, retail, and individual investors. Approximately 55.17% of the company’s stock is owned by Institutional Investors, 18.11% is owned by Insiders, and 10.34% is owned by Public Companies and Individual Investors.

Recent Insider Trading Activity

Date
Name
Activity
Value
Jan 13, 2025
Jerome Charles Bressi
Chief Regulatory And Quality Officer
xxxxxxxxxxxxx
$9269
Jan 13, 2025
Cindy Tahl
Chief Legal & Compliance Officer And Secretary
xxxxxxxxxxxxx
$8764
Jan 13, 2025
Bahram Valamehr
President & Ceo,director
xxxxxxxxxxxxx
$13406
Dec 26, 2024
Redmile Group, Llc
Director, >10% Owner
xxxxxxxxxxxxx
$668580

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Dec 31, 2024
xxxxxxxxxxxxx
$36864
Dec 31, 2024
xxxxxxxxxxxxx
$2347595
Dec 31, 2024
xxxxxxxxxxxxx
$5376363

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
12,884,277Insider11.24%12,124,105
4,945,146Insider5.00%4,653,382
5,251,391Institution4.58%4,941,559
4,760,605Institution4.15%4,479,729
4,453,203Institution3.89%4,190,464
3,555,871Institution3.10%3,346,075
3,258,402Institution2.84%3,066,156
2,904,835Institution2.53%2,733,450
1,422,785Institution1.24%1,338,841
1,361,334Institution1.19%1,281,015

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
4,453,203Institution3.89%4,190,464
2,904,835Institution2.53%2,733,450
1,361,334Institution1.19%1,281,015
1,268,133Institution1.11%1,193,313
1,138,815Institution0.99%1,071,625
1,034,885Institution0.90%973,827
904,537Institution0.79%851,169
545,614Institution0.48%513,423
510,751Institution0.45%480,617
506,501Institution0.44%476,617

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
3,049,285Institution2.66%3,415,199
2,945,465Institution2.57%2,773,155
1,403,918Institution1.23%1,572,388
904,289Institution0.79%851,388
632,061Institution0.55%596,350
595,123Institution0.52%560,308
449,884Institution0.39%503,870
420,847Institution0.37%397,069
275,014Institution0.24%308,016
260,415Institution0.23%245,702

FAQ

Who Owns Fate Therapeutics (FATE)?
According to the latest TipRanks data, approximately 39.29% of the company's stock is held by institutional investors, 18.11% is held by insiders, and 16.39% is held by retail investors.
    What percentage of Fate Therapeutics (FATE) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 39.29% of Fate Therapeutics (FATE) stock is held by institutional investors.
      What percentage of Fate Therapeutics (FATE) stock is held by retail investors?
      According to the latest TipRanks data, approximately 16.39% of Fate Therapeutics (FATE) stock is held by retail investors.
        Who owns the most shares of Fate Therapeutics (FATE)?
        Redmile Group, Llc owns the most shares of Fate Therapeutics (FATE).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis